C9orf72 and frontotemporal dementia: The involvement of the C9orf72 carrier community at all stages of prevention trial planning and execution will be critical for success, as outlined in the US Food and Drug Administration (FDA) guidance series of Patient Focused Drug Development.22 Input should also be drawn from people having family experience with both ALS and FTD.